Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

The cousin of Robert F Kennedy Jr – President Trump's pick to lead the Department of Health and Human Services (HHS) – has ...

The alliance will pair EVERSANA's NAVLIN platform, which provides data and information on global pricing and market access, ...

As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the ...

At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

As scientific discovery and technology advance, new opportunities arise and business priorities shift throughout the global ...